1 4 2 9 l e t t e r S Aberrant activation of the Hedgehog (Hh) pathway can drive tumorigenesis 1 . To investigate the mechanism by which glioma-associated oncogene family zinc finger-1 (GLI1), a crucial effector of Hh signaling 2 , regulates Hh pathway activation, we searched for GLI1-interacting proteins. We report that the chromatin remodeling protein SNF5 (encoded by SMARCB1, hereafter called SNF5), which is inactivated in human malignant rhabdoid tumors (MRTs), interacts with GLI1. We show that Snf5 localizes to Gli1-regulated promoters and that loss of Snf5 leads to activation of the Hh-Gli pathway. Conversely, re-expression of SNF5 in MRT cells represses GLI1. Consistent with this, we show the presence of a Hh-Gli-activated gene expression profile in primary MRTs and show that GLI1 drives the growth of SNF5-deficient MRT cells in vitro and in vivo. Therefore, our studies reveal that SNF5 is a key mediator of Hh signaling and that aberrant activation of GLI1 is a previously undescribed targetable mechanism contributing to the growth of MRT cells.
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The Hh pathway has critical functions in tissue patterning and differentiation during development 1 . Aberrant activation of the pathway resulting from mutations in the PTCH1 gene (encoding Patched-1 receptor) and SMO gene (encoding the Smoothened homolog signal transducer) contribute to medulloblastoma and basal cell carcinomas 3, 4 . In addition, amplifications in the GLI1 transcription factor occur in gliomas and medulloblastomas 5, 6 , and the oncogenic potential of GLI1 has been validated in transgenic mouse models 2 . However, understanding of the precise mechanisms by which GLI transcription factors are regulated is limited. We thus sought to investigate the mechanism by which GLI1 controls pathway activation.
We performed affinity purification-mass spectrometry (AP-MS) to identify proteins that interact with GLI1. We used tandem affinity purification (TAP) to isolate GLI1 from mouse TM3 cells ( Supplementary   Fig. 1a,b) , a Hh-responsive testicular epithelial cell line, and identified interacting proteins (Fig. 1a) . The top-scoring interactor was Sufu, a bona fide GLI1-interacting protein that negatively regulates its activity 7 . Notably, the chromatin remodeling protein Snf5 (E = 0.0022, false discovery rate P value = 0.0022) and several other SWI/SNF complex subunits, Smarcc2 (E = 0.0186, P = 0.0093) and Smarce1 (E = 0.0005, P = 0.0005), were among the top interactors of GLI1 (Fig. 1a) . AP-MS experiments with TAP-tagged GLI2, however, did not yield Snf5 or its associated complex members (data not shown), thereby showing specificity in the interaction of Snf5 with GLI1. To confirm the interaction, we performed immunoprecipitation of endogenous Snf5 in TM3 cells transiently expressing GLI1 and found that GLI1 immunoprecipitated with Snf5 (Fig. 1b) . As a control, we repeated this with SNF5-deficient G401 human MRT cells. We did not detect GLI1 in this case (Supplementary Fig. 1c ), confirming that GLI1 is only immunoprecipitated in the presence of Snf5. In TM3 cells transiently expressing various GLI1 deletion mutants, we localized the interaction domain to the C terminus of GLI1 outside of the activation domain ( Supplementary Fig. 2a-c) ; this is a region less conserved among the three GLI proteins, supporting a specific interaction between Snf5 and GLI1.
Snf5 is a core member of the ATP-dependent SWI-SNF chromatin remodeling complex, which contributes to regulation of gene expression via modulation of chromatin structure [8] [9] [10] . Because Ptch1 is a target of GLI1, as is Gli1 itself 11, 12 , we determined if Snf5 associates with Gli1-regulated promoters by chromatin immunoprecipitation (ChIP), (Fig. 1c) . Both Snf5 and GLI1 were enriched at regions upstream of the transcriptional start sites of both promoters (Fig. 1d,e) .
We next tested the effect of shRNA-mediated knockdown of Snf5 upon the expression of the Gli1 target genes Gli1 and Ptch1 11, 12 ( Fig. 2a) and found both to be upregulated (Fig. 2b) . This is unlikely to be influenced by changes in expression of other Hh pathway components, as the expression of Smo and Gli2 remained unaffected (Fig. 2b) Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway l e t t e r S and Hh ligands remained undetectable (data not shown). We further investigated this regulation in Snf5 conditional knockout primary mouse embryonic fibroblasts (MEFs) 13 . Inactivation of Snf5 (Fig. 2c) resulted in an eight-to tenfold increase in Gli1 expression (Fig. 2d) and an approximately twofold increase in Ptch1 expression (Supplementary Fig. 3a) . As the SWI-SNF complex regulates nucleosome mobilization, we evaluated the effects of Snf5 inactivation on nucleosome distribution at Gli1-target promoters and found that it led to a significant (P < 0.05 for Gli1 gene and P < 0.001 for Ptch1, Fisher's exact test) decrease in the density of nucleosomes at the Gli1 and Ptch1 promoters ( Supplementary Fig. 4a,b) . We evaluated whether Snf5 controls Gli1 expression during normal development in vivo. As the Hh pathway serves a key role in limb patterning, we used the Paired related homeobox (Prx1)-Cre transgenic mouse line 14, 15 to inactivate Snf5 in the early limb bud mesenchyme. We then examined the consequences of Snf5 inactivation during early limb development. Gli1 transcripts are normally restricted to the posterior half of the developing limb ( Inactivation of Snf5 led to markedly increased levels of Gli1 as well as ectopic expression throughout both anterior and posterior fields (Fig. 2e) . Therefore, in all three experimental contexts, loss of Snf5 leads to the upregulation of Gli1, demonstrating that Snf5 normally has a role in restraining Hh-Gli signaling.
Snf5 and Brg1 are similar in that they are both bona fide tumor suppressors and core subunits of the SWI-SNF complex. However, the relationship between the two is complex, as residual activity of Brg1 is essential for lymphoma formation driven by Snf5 inactivation 17 . We therefore investigated their relationship in the regulation of Gli1 activity. Inactivation of Brg1 also resulted in a substantial increase in Gli1 expression ( Supplementary Fig. 5a,b) , as did concurrent inactivation of Snf5 and Brg1 ( Supplementary  Fig. 5b ). This suggests that Gli1 is a common target of the SWI-SNF complex and may be central to the tumor suppressor activity of both Snf5 and Brg1.
Biallelic inactivation of SNF5 occurs in a majority of MRTs, which are poorly differentiated cancers arising in the kidney, brain (atypical teratoid rhabdoid tumors), liver and soft tissues [18] [19] [20] . Notably, SNF5-deficient tumor cells are diploid and genomically stable, suggesting that the major driver of malignancy upon SNF5 loss consists of changes in epigenetically driven transcriptional control of gene expression 21, 22 . We hypothesized that the Hh-Gli pathway is aberrantly activated in SNF5-deficient MRT cells. GLI1 mRNA expression was indeed higher in MRT cell lines than in cancer cell lines of various origins (Fig. 3a) . Re-expression of SNF5 in two independent SNF5-deficient MRT cell lines ( Fig. 3b and Supplementary Fig. 6a ) led to a marked suppression of GLI1 mRNA ( Fig. 3c and Supplementary  Fig. 6b ). Therefore, SNF5-induced repression of GLI1 in MRT cells is consistent with our findings that Snf5 deficiency results in hyperactivation of the Hh-Gli pathway. Taken together, these findings suggest that Snf5 normally is involved in limiting Gli1 expression. GLI1-shRNA-1 vehicle GLI1-shRNA-1 dox l e t t e r S we analyzed microarray data from eight primary brain rhabdoid tumors, three MRT cell lines, 11 normal cerebellum samples and 25 primary medulloblastomas 13, 23 . A subset of these medulloblastomas have genetic mutations in PTCH1 and show an activated Hh pathway gene expression profile, thus serving as positive controls in our analyses 23 . Primary SNF5-deficient tumors indeed showed enrichment of gene expression associated with both Hh pathway activation (P = 2.72 × 10 −6 ), and GLI1 overexpression signatures (P = 0.0063) (Fig. 3d) , similar to Hh-activated medulloblastomas (P = 0.00207 for the Hh pathway and P = 0.00298 for the GLI1 overexpression gene sets) and to basal cell carcinomas (P = 1.19 × 10 −7 ), which often possess activating mutations in the Hh pathway (Fig. 3d) . A Snf5-null gene expression signature 13 and CYCLIN-D1 overexpression signature were used as controls 24 , showing expected trends in the primary rhabdoid tumors (Supplementary Fig. 7a ).
We next evaluated whether upregulation of GLI1 is required for the proliferation of SNF5-deficient cells. Doxycyline-inducible, shRNAmediated knockdown of GLI1 in three MRT cell lines (Fig. 4a and  Supplementary Fig. 8a ) resulted in impaired proliferation (Fig. 4b-d and Supplementary Fig. 8c,d ) as well as in the inhibition of colony formation (Fig. 4e) . Proliferation was rescued by overexpression of a doxycycline-inducible GLI1 construct not containing the shRNA recognition sequence (Fig. 4c) . To determine whether GLI1 is necessary for the growth of rhabdoid tumors in vivo, we established subcutaneous xenografts of G401 cells in severe combined immunodeficient (SCID) mice, which lack T and B cells, using the doxycyclineinducible cells. In contrast to vehicle treatments, treatment of mice with doxycycline depleted GLI1 protein (Supplementary Fig. 8b ) and markedly inhibited tumor growth (Fig. 4f) . Treatment of MRT cells with a small-molecule inhibitor of GLI, Hedgehog pathway inhibitor-1 (HPI-1) 25 , similarly led to dose-dependent decreases in GLI1 transcripts and inhibition of cell proliferation ( Supplementary  Fig. 9a-d) . In contrast, treatment with a highly specific SMO antagonist, NVP-LDE225 (ref. 26 ) had no effect on GLI1 expression or proliferation of SNF5-deficient MRT cells ( Supplementary  Figs. 10a-d) , as would be expected if Hh activation occurs downstream of SMO through activation of GLI1. Collectively, these results show an essential role for GLI1 in the proliferation of SNF5-deficient cancer cells. Finally, our preliminary findings indicate that Snf5 interacts with GLI1 even upon stimulation of the pathway with an agonist (Supplementary Fig. 11a,b) . This suggests that Snf5 could functionally prevent hyperactivation of the pathway, although the precise mechanisms will need to be addressed.
Transcriptional activity is regulated by nucleosome position and density, with more open chromatin structure and decreased nucleosomal density occurring at the promoters of highly transcribed genes. Our findings suggest a model whereby the SWI-SNF complex physically interacts with GLI1 to directly regulate activity of the Hh pathway via control of chromatin structure at GLI1 target promoters. Although we have demonstrated that the tumor-suppressor effects of SNF5 require interaction with GLI1, SNF5 has other interactions of potential cancer relevance, such as with the oncoprotein c-Myc and the tumor suppressor p53 (refs. 27-30) . We thus suggest a mechanistic model whereby loss of SNF5 drives cancer formation through simultaneous epigenetic perturbation of GLI1 and other key cancer-promoting pathways, several of which may thus constitute viable therapeutic targets.
In evaluating the relevance of SNF5 regulation of GLI1, we show that SNF5-deficient MRT cells have hyperactivated GLI signaling, which has a role in their growth. Our studies reveal a previously undiscovered mechanism controlling the Hh pathway that has potential therapeutic implications for an aggressive cancer for which no targeted therapy currently exists. For cancers with proximal activation of the Hh pathway, treatment with SMO inhibitors has shown clinical efficacy and little toxicity 31 . However, as Hh pathway activation can occur downstream of SMO, as we demonstrate in SNF5-deficient MRT cells, our studies provide further understanding and a rationale for the inhibition of GLI1 in targeted cancer treatment.
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